A- A A+

HCV treatment initiation in the era of universal direct acting antiviral coverage - Improvements in access and persistent barriers. 

Jiang N, Bruneau J, Makarenko I, Minoyan N, Zang G, Høj SB, Larney S, Martel-Laferrière V. 

Int J Drug Policy. 2023 Feb 7;113:103954. doi: 10.1016/j.drugpo.2023.103954. Epub ahead of print. PMID: 36758334.

https://www.sciencedirect.com/science/article/pii/S0955395923000038

Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey. 

Di Ciaccio M, Villes V, Perfect C, El Kaim JL, Donatelli M, James C, Easterbrook P, Delabre RM. 

Harm Reduct J. 2023 Feb 9;20(1):15. doi: 10.1186/s12954-023-00743-8. PMID: 36759855; PMCID: PMC9909907.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909907/

Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable. 

McDonald, SA, Myring, G, Palmateer, NE, et al. 

Addiction. 2023: 000– 000. doi.org/10.1111/add.16169

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.16169

Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework. 

Lafferty, L, Sheehan, Y, Cochrane, A, Grebely, J, Lloyd, AR, Treloar, C. 

Addiction. 2023. doi.org/10.1111/add.16137

https://onlinelibrary.wiley.com/doi/full/10.1111/add.16137

How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States. 

Walters SM, Frank D, Felsher M, Jaiswal J, Fletcher S, Bennett AS, Friedman SR, Ouellet LJ, Ompad DC, Jenkins W, Pho MT. 

Int J Drug Policy. 2023 Jan 13;112:103930. doi: 10.1016/j.drugpo.2022.103930. Epub ahead of print. PMID: 36641816.

https://www.sciencedirect.com/science/article/pii/S0955395922003462

Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update. 

Roebuck MC. 

Am J Manag Care. 2022 Dec;28(12):630-631. doi: 10.37765/ajmc.2022.89273. PMID: 36525655.

https://www.ajmc.com/view/impact-of-direct-acting-antiviral-use-for-chronic-hepatitis-c-on-health-care-costs-in-medicaid-economic-model-update

Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. 

Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. 

Int J Drug Policy. 2023 Jan;111:101670. doi: 10.1016/j.drugpo.2015.11.010. Epub 2015 Nov 28. PMID: 26749563.

Zusammenfassung

https://www.sciencedirect.com/science/article/abs/pii/S0955395915003527

Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. 

Haque LY, Fiellin DA, Tate JP, et al. 

JAMA Netw Open. 2022;5(12):e2246604. doi:10.1001/jamanetworkopen.2022.46604

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799555

RKI-Themenseite Hepatitis C

https://www.rki.de/DE/Content/InfAZ/H/HepatitisC/Point-Studie.html

Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts. 

Robinson, E., Byrne, C.J., Carberry, J. et al.

BMC Public Health 23, 54 (2023). doi.org/10.1186/s12889-022-14911-1

https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-14911-1

Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder. 

Lier AJ, Vander Wyk B, Di Paola A, Springer SA. 

Open Forum Infect Dis. 2022 Nov 14;9(11):ofac624. doi: 10.1093/ofid/ofac624. PMID: 36467300; PMCID: PMC9709708.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709708/

Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users. 

Huang G, Cheng W, Xu Y, Yang J, Jiang J, Pan X, Zhou X, Jiang J, Chai C. 

Int J Environ Res Public Health. 2022 Nov 25;19(23):15677. doi: 10.3390/ijerph192315677. PMID: 36497751; PMCID: PMC9738321.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738321/

Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C

Bobzin C, Bösiger Ch, Bruggmann P et al.

Swiss Med Forum. 2021;21(1112):184-186, Veröffentlichung: 17.03.2021, doi.org/10.4414/smf.2021.08756 

https://medicalforum.ch/de/detail/doi/smf.2021.08756

HCV elimination in a Swiss opioid agonist therapy programme - a cohort study. 

Bregenzer A, Krismer C, Wendel S, Roser P, Fux CA. 

Swiss Med Wkly. 2022 Dec 9;152:40009. doi: 10.57187/smw.2022.40009. PMID: 36509421.

https://smw.ch/index.php/smw/article/view/3257

Zu wenige Menschen mit Hepatitis C in Therapie

Eine chronische Leberentzündung verursacht durch das Hepatitis C-Virus (HCV) kann viel Leid und schwerwiegende Spätfolgen wie Krebs mit sich bringen. Doch so weit muss es nicht kommen: Dank moderner Therapiemöglichkeiten ist die Heilung der Infektionskrankheit nicht die Ausnahme, sondern die Regel. Laut Daten des Robert Koch-Instituts (RKI) werden in Deutschland aktuell aber zu wenige Patient:innen behandelt. (Pharma Fakten, 02.11.2022)

https://pharma-fakten.de/grafiken/zu-wenige-menschen-mit-hepatitis-c-in-therapie/

Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus. 

Bar N, Bensoussan N, Rabinowich L, Levi S, Houri I, Ben-Ami Shor D, Shibolet O, Mor O, Weitzman E, Turner D, Katchman H.

Int J Environ Res Public Health. 2022 Nov 18;19(22):15237. doi: 10.3390/ijerph192215237. PMID: 36429957.

Https://www.mdpi.com/1660-4601/19/22/15237

Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.

Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Nevens F, Hens N, Robaeys G. 

BMC Public Health. 2022 Nov 24;22(1):2159. doi: 10.1186/s12889-022-14623-6. PMID: 36419013; PMCID: PMC9685883.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685883/

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. 

Sarıgül Yıldırım F, Üser Ü, Sarı ND, Kurtaran B, Önlen Y, Şenateş E, Gündüz A, Zerdali E, Karsen H, Batırel A, Karaali R, Güner R, Yamazhan T, Köse Ş, Erben N, İnce N, Köksal İ, Çuvalcı Öztoprak N, Yörük G, Kömür S, Bal T, Kaya S, Bozkurt İ, Günal Ö, Yıldız İE, İnan D, Barut Ş, Namıduru M, Tosun S, Türker K, Şener A, Hızel K, Baykam N, Duygu F, Bodur H, Can G, Gül HC, Sağmak Tartar A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F. 

Turk J Gastroenterol. 2022 Nov;33(11):971-978. doi: 10.5152/tjg.2022.21834. PMID: 36415900.

https://www.turkjgastroenterol.org/en/in-a-real-life-setting-direct-acting-antivirals-to-people-who-inject-drugs-with-chronic-hepatitis-c-in-turkey-136976

History of alcohol use does not predict HCV direct acting antiviral treatment outcomes. 

Ia Okwor C, Petrosyan Y, Lee C, Cooper C. 

J Assoc Med Microbiol Infect Dis Can. 2022 Sep 27;7(3):233-241. doi: 10.3138/jammi-2021-0037. PMID: 36337601; PMCID: PMC9629724.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629724/

Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States. 

Chen PH, Yenokyan K, Fojo AT, Hutton HE, Lesko CR, McCaul ME, Yang C, Cachay ER, Crane HM, Jacobson JM, Kim HN, Kitahata MM, Mayer KH, Moore RD, Napravnik S, Saag M, Lau B, Chander G. 

Drug Alcohol Depend. 2022 Oct 22;241:109673. doi: 10.1016/j.drugalcdep.2022.109673. Epub ahead of print. PMID: 36332596.

https://www.sciencedirect.com/science/article/pii/S0376871622004100

EASL recommendations on treatment of hepatitis C: Final update of the series

Pawlotsky, Jean-MichelNegro, FrancescoAghemo, Alessio et al.

Journal of Hepatology, Volume 73, Issue 5, 1170 - 1218 

https://www.journal-of-hepatology.eu/article/S0168-8278(20)30548-1/fulltext

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates. 

Lens S, Miralpeix A, Gálvez M, Martró E, González N, Rodríguez-Tajes S, Mariño Z, Saludes V, Reyes-Urueña J, Majó X, Colom J, Forns X. 

JHEP Rep. 2022 Sep 13;4(12):100580. doi: 10.1016/j.jhepr.2022.100580. PMID: 36316992; PMCID: PMC9617206.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617206/

Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.

Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. 

J Infect Dis. 2022 Aug 26;226(3):431-440. doi: 10.1093/infdis/jiaa359. PMID: 32584386; PMCID: PMC9417129.

https://pubmed.ncbi.nlm.nih.gov/32584386

HIV? Hepatitis? Das CHECK ich! 

Modellprojekt zu Beratungen und Tests für Menschen, die Drogen gebrauchen, durchgeführt in niedrigschwelligen Einrichtungen der Drogenhilfe.

Abschlussbericht zu den Ergebnissen der Begleitevaluation

Herausgeberin: Bundeszentrale für gesundheitliche Aufklärung (BZgA), Juli 2020

https://www.liebesleben.de/fachkraefte/sexualaufklaerung-und-praeventionsarbeit/richtigen-zugang/

Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020. 

Thompson WW, Symum H, Sandul A, et al. 

MMWR Morb Mortal Wkly Rep 2022;71:1011-1017. doi.org/10.15585/mmwr.mm7132e1

https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e1.htm

Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel. 

Fiore V, De Matteis G, Pontali E, De Vito A, Panese S, Geremia N, Maida I, Artioli S, Starnini G, Madeddu G, Babudieri S. 

Front Public Health. 2022 Oct 4;10:926414. doi: 10.3389/fpubh.2022.926414. PMID: 36268000; PMCID: PMC9577224.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577224/

Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). 

Palmateer N, Hamill V, Bergenstrom A, Bloomfield H, Gordon L, Stone J, Fraser H, Seyler T, Duan Y, Tran R, Trayner K, Biggam C, Smith S, Vickerman P, Hickman M, Hutchinson S. 

Int J Drug Policy. 2022 Nov;109:103872. doi: 10.1016/j.drugpo.2022.103872. Epub 2022 Oct 3. PMID: 36202039.

https://www.sciencedirect.com/science/article/pii/S0955395922002882

Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic. 

Losikoff P, Bosse JD, Martin SA, Wilson A, Chiodo LM. 

Front Psychiatry. 2022 Sep 14;13:932306. doi: 10.3389/fpsyt.2022.932306. PMID: 36186876; PMCID: PMC9515307.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515307/

Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study). 

Rolland B, Lions C, Di Beo V, Carrieri P, Authier N, Barré T, Delorme J, Mathurin P, Bailly F, Protopopescu C, Marcellin F. 

Harm Reduct J. 2022 Oct 27;19(1):119. doi: 10.1186/s12954-022-00702-9. PMID: 36303159; PMCID: PMC9615191.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615191/

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort). 

Barré T, Bourlière M, Ramier C, Carrat F, Di Beo V, Protopopescu C, Marcellin F, Bureau M, Cagnot C, Dorival C, Zoulim F, Zucman-Rossi J, Duclos-Vallée JC, Fontaine H, Carrieri P, The Anrs/Afef Hepather Study Group. 

J Clin Med. 2022 Oct 18;11(20):6135. doi: 10.3390/jcm11206135. PMID: 36294456; PMCID: PMC9605108.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605108/

  1. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. 
  2. The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection. 
  3. WHO-Empfehlungen: Hepatitis C ließe sich eliminieren
  4. Neuer Check-up für die Leber: Warum Hepatitis-Tests so sinnvoll sind
  5. Impact of an Accelerated Pretreatment Evaluation on Linkage-to-Care for Hepatitis C-infected Persons Who Inject Drugs.